Synopsis A clinical study evaluates the mosaic adenovirus serotype 26 (Ad26)-based HIV-1 vaccine candidates in parallel clinical (human) and preclinical (rhesus monkey) studies to outline the optimal vaccine regimen; and the safety, tolerability, and immunogenicity of the vaccine regimens. This week's 'MED FACT' discusses a clinical trial from The Lancet , “ Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomized, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19) ” . 2018. Authors : Barouch D.
et al. Key Takeaways The mosaic Ad26/Ad26 plus high-dose gp140 HIV-1 vaccine induced robust and comparable immune responses in humans and rhesus monkeys; with considerable protection against repetitive HIV challenges in rhesus monkeys. Ob jective Study Type Participants To evaluate a mosaic HIV-1 vaccine in humans and rhesus…
